sales@dcchemicals.com
Lipid TD5
Formulation & Performance
Formulation & Performance
Study-specific compositions, preparation conditions and experimental outcomes for TD5.
Publisher abstract rechecked. Previously extracted composition and characterization are retained separately; full-text/SI dose-and-time verification remains incomplete in this revision.
1. Formulations and component amounts
Reported composition and calculated mass are separate. Molecular-weight inputs use the current catalog values; DMG-PEG2000 is fixed initially at 2507. Edit inputs only when using a verified alternative material.
TD5 BLNP
mol%Prior product extraction; full Methods recheck pending
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| TD5 | 50.000 | 83.2018 | 56.5906 | ||
| DOPE | 10.000 | 16.6404 | 12.3809 | ||
| Cholesterol | 38.500 | 64.0654 | 24.7709 | ||
| DMG-PEG2000 | 1.500 | 2.4961 | 6.2576 |
Calculated total: 100.0000 mg lipid. RNA, solvent and process loss are excluded.
How component weights are calculated
For total lipid mass M (mg), molar parts rᵢ and molecular weight MWᵢ: component mass = M × rᵢ × MWᵢ / Σ(r × MW). Component amount (µmol) = component mass (mg) × 1000 / MWᵢ. Molar parts are normalized only for the displayed percentage. The calculation does not infer N/P or RNA dose.
2. Preparation and experimental setup
| Parameter | Reported procedure / limitation | Source |
|---|---|---|
| Administration | Intrathecal delivery is the route supported by the publication abstract. It is not evidence for systemic crossing of the blood–brain barrier. | Publisher abstract |
| Recipe / N/P | Prior record gives the four-component composition above. N/P, phase ratio, mixing flow and purification have not been re-verified from complete Methods. | Prior extraction; primary protocol pending |
| Dose mapping | The earlier record lists 0.135 mg/kg for a mouse intrathecal experiment. That dose has not been independently mapped to every GFP, Cre and CRISPR endpoint in this revision. | Not propagated into all result rows |
3. Particle characterization
| Measurement / batch | Reported result | Evidence context |
|---|---|---|
| Earlier particle-size record | 107.5 nm | Prior extraction; primary figure recheck pending |
| Earlier encapsulation record | 81.7% | Prior extraction; primary figure recheck pending |
| Earlier apparent pKa record | 7.3, TNS assay | Prior extraction; primary assay recheck pending |
4. Performance by experiment
| Experiment and dose | Readout and comparator | Result and source |
|---|---|---|
| GFP expression Mouse brain; TD5 BLNP–GFP mRNA; single intrathecal injection | Readout: Dose/time not specified in the accessible abstract Comparator: MC3 LNP comparison described by the authors | Reported GFP-positive neurons 29.6% and astrocytes 38.1%. These are cell-population percentages, not brain fraction of injected dose.Publisher abstract |
| Cre reporter recombination Ai14 mice; TD5 BLNP–Cre mRNA; intrathecal | Readout: Dose/time not specified in the accessible abstract Comparator: Study reporter controls | Approximately 30% of neurons and 40% of astrocytes showed tdTomato expression across major brain regions. These values are not Cas9 editing efficiencies.Publisher abstract |
| CRISPR delivery TD5 BLNP carrying Cas9 mRNA/sgRNA; mouse brain | Readout: Dose/time and numerical editing rate require full text Comparator: Study editing controls | The abstract reports effective brain genome editing; no exact percentage is supplied here.Publisher abstract |
5. Interpretation and unresolved details
- Full paper and SI are still needed for dose, volume, injection site, readout time, replicate count, statistics and exact preparation details.
- The mass worksheet is based on the earlier extracted composition and current catalog values; it is not an independently re-verified administration protocol.
- Intrathecal delivery and systemic brain targeting are different experimental claims.
- GFP expression, Cre recombination and Cas9 editing must remain separate endpoints.
Results apply to the stated LNP composition, cargo, process, dose, route and model. LNP experimental measurements are not batch-release specifications for the isolated lipid.
6. References and data access
Xue Y, et al. Lipid Nanoparticles Enhance mRNA Delivery to the Central Nervous System Upon Intrathecal Injection. Advanced Materials. 2025;37(27):2417097. DOI: 10.1002/adma.202417097
Download experiment table (CSV) · Open printable Formulation & Performance guide
Revision FP-20261022 · Source review: 22 October 2026 · DC Chemicals